BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
The collaboration is focused on using [F-18]MK-6240 as a biomarker in Eisai neurodegenerative disease research studies. The companies will collaborate to evaluate the effect of investigational therapeutics on the potential treatment of neurodegenerative diseases in humans.
“Cerveau is focused on enhancing access to key technologies that we believe have the potential to advance human health,” said Rick Hiatt, chief executive officer, Cerveau Technologies, Inc. “We are excited to welcome Eisai to our growing network of pharmaceutical partners and global production sites. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.
About Eisai Inc.
Eisai Inc. is a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at Eisai.com/us.